• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Teligent, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    9/24/21 4:57:27 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care
    Get the next $TLGT alert in real time by email
    0000352998 false --12-31 0000352998 2021-09-20 2021-09-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): September 20, 2021

     

    TELIGENT, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   001-08568   01-0355758
    (State or other jurisdiction    (Commission File Number)   (I.R.S. Employer
    of incorporation)       Identification No.)

     

    105 Lincoln Avenue

    Buena, New Jersey 08310

    (Address of Principal Executive Offices)(Zip Code)

     

    Registrant’s telephone number, including area code: (856) 697-1441

     

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, par value $0.01 per share TLGT The NASDAQ Stock Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company. ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 3.03Material Modification to Rights of Security Holders

     

    The disclosure set forth in Item 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.

     

    Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

     

    On September 20, 2021, the Board of Directors (the “Board”) of Teligent, Inc. (the “Company”) approved Amended and Restated Bylaws, which became effective immediately. The amendments effected by the Amended and Restated Bylaws include (i) adding a forum selection clause that generally requires litigation regarding internal corporate claims to be brought in the Court of Chancery of the State of Delaware, (ii) consistent with the Company’s Amended and Restated Certificate of Incorporation, as amended, providing for indemnification of current and former directors and executive officers in connection with proceedings brought against them arising out of their service as directors or executive officers, and (iii) updating changes in light of, among other items, changes in Delaware law relating to electronic communications, virtual meetings and other matters.

     

    The foregoing description of the Amended and Restated Bylaws is only a summary and is qualified in its entirety by reference to the full text of the Amended and Restated Bylaws, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

     

    Item 9.01Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No. Exhibit Description
    3.1 Amended and Restated Bylaws

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    TELIGENT, INC.

       
    Date: September 24, 2021 By:

    /s/ Philip K. Yachmetz

        Name: Philip K. Yachmetz
        Title: Executive Vice President, Chief Legal Officer & Corporate Secretary

     

     

    Get the next $TLGT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLGT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TLGT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Benesch Joseph

    3 - Teligent, Inc. (0000352998) (Issuer)

    10/8/21 4:31:06 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form 3 filed by new insider Lozynski Alyssa

    3 - Teligent, Inc. (0000352998) (Issuer)

    10/7/21 11:09:36 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Celentano John E

    4 - Teligent, Inc. (0000352998) (Issuer)

    7/22/21 5:04:00 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    SEC Filings

    View All

    SEC Form 25-NSE filed by Teligent, Inc.

    25-NSE - Teligent, Inc. (0000352998) (Subject)

    10/27/21 9:46:36 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Teligent, Inc. (0000352998) (Filer)

    10/15/21 4:35:51 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. filed SEC Form 8-K: Leadership Update

    8-K - Teligent, Inc. (0000352998) (Filer)

    9/27/21 5:02:29 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teligent to Pursue Asset Sale through Voluntary Chapter 11 Process

    BUENA, N.J., Oct. 14, 2021 /PRNewswire/ -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company ("Teligent" or the "Company"), today announced that the Company has, together with certain of its affiliates, filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware to pursue a sale process that is intended to maximize the value of the Company. The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several interested parties. The Company expects to consummate a sale of the entire busi

    10/14/21 6:15:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update

    –Update on FDA Inspection of Buena Facility–Assessing New Growth Opportunities in Injectables–Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time –Dial in: (877) 407-0792 US Toll Free Number  (201) 689-8263 International Number  Confirmation Number: 13721972 BUENA, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a business update. "Product demand in our core business was impacted by a combination of factors, including remediation-related activities, the ongoing effects of the COVID-19 pandemic, and modest ge

    8/16/21 7:00:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. to Hold Conference Call for Second Quarter 2021 Financial Results on Monday, August 16, 2021

    BUENA, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June 30, 2021 financial results and business update. Conference Call InformationDate: Monday, August 16, 2021Time: 8:30 a.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0792 International: 201-689-8263Conference ID: 13721972 This call is available via webcast and can be accessed under News & Events in the Investor Relations section of Teligent, Inc.'s website at www.teligent.com. About Teligent, Inc.T

    8/11/21 4:05:00 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Leadership Updates

    Live Leadership Updates

    View All

    Teligent Announces Hiring of Chief Financial Officer

    BUENA, N.J., April 15, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT) ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced the hiring and appointment of Ernest R. De Paolantonio as Chief Financial Officer of the Company, effective April 15, 2021. Timothy B. Sawyer, President and CEO of the Company, commented, "We are very pleased that Ernie has agreed to join our Teligent team. Over the last several months, we have made key additions to our leadership team, and the appointment of Ernie to the CFO position reflects our commitment to bring in highly talented and experienced individuals who have a strong track record of success. E

    4/15/21 7:30:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces Appointment of Carter Pate to Board of Directors

    BUENA, N.J., Feb. 23, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed Carter Pate to its Board of Directors, effective immediately. Mr. Pate will serve on the Audit and Nominating and Corporate Governance Committees. Mr. Pate leads a family-owned investment firm and serves on the Board of Directors at multiple companies, including Global Step and Advanced Emissions Solutions, Inc. He excels at leading companies through moments of change to drive business objectives and redefine their possibilities for growth.    John Celentano, Chairman of Teligent's Board of Dire

    2/23/21 7:30:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces Appointment of William S. Marth to Board of Directors

    BUENA, N.J., Feb. 16, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed industry veteran William S. Marth to its Board of Directors, effective immediately. Mr. Marth brings over 25 years of expertise and a proven track record of leading companies in the generic pharmaceutical and contract manufacturing industries. John Celentano, Chairman of Teligent's Board of Directors, commented on the appointment, stating that "We are excited to have Bill join Teligent's Board of Directors. He is a strategic leader with extensive experience in helping businesses transform and

    2/16/21 7:30:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Financials

    Live finance-specific insights

    View All

    Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update

    –Update on FDA Inspection of Buena Facility–Assessing New Growth Opportunities in Injectables–Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time –Dial in: (877) 407-0792 US Toll Free Number  (201) 689-8263 International Number  Confirmation Number: 13721972 BUENA, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a business update. "Product demand in our core business was impacted by a combination of factors, including remediation-related activities, the ongoing effects of the COVID-19 pandemic, and modest ge

    8/16/21 7:00:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. to Hold Conference Call for Second Quarter 2021 Financial Results on Monday, August 16, 2021

    BUENA, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June 30, 2021 financial results and business update. Conference Call InformationDate: Monday, August 16, 2021Time: 8:30 a.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0792 International: 201-689-8263Conference ID: 13721972 This call is available via webcast and can be accessed under News & Events in the Investor Relations section of Teligent, Inc.'s website at www.teligent.com. About Teligent, Inc.T

    8/11/21 4:05:00 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces First Quarter 2021 Earnings Report and Provides Business Update

    –Continued Remediation Progress Being Made–Reiterating Prior Guidance of Informing FDA on Inspection Readiness During 3Q2021–Conference Call to Be Held on May 25, 2021 at 4:30 pm Eastern Standard Time –Dial in: (800) 708-4540 US Toll Free Number  (847) 619-6397 US Number  Confirmation Number: 50161966 BUENA, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the first quarter of 2021 and provided a business update. "As we prepare for the second half of 2021, we are pleased with the progress being made with respect to remediation, our strengthened capital position, and the recent

    5/25/21 7:00:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - Teligent, Inc. (0000352998) (Subject)

    2/16/21 4:30:32 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Teligent, Inc. (0000352998) (Subject)

    2/16/21 12:02:06 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G filed

    SC 13G - Teligent, Inc. (0000352998) (Subject)

    2/16/21 10:39:59 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care